pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,871 stories · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints579BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps22
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology6
  • Merck stages expanded access to monthly HIV PrEP pill ahead of approval
    Following in the footsteps of Gilead, Merck has signed voluntary licensing agreements to enable access to its investigational HIV PrEP pill alimatravir ahead of any regulatory submissions.
    Fierce Biotech · 12h ago↗ source
  • Opinion: I may be one of the last middle-class medical students who could afford to become a doctor
    A federal loan program made it possible for Gauri Gurumurthy to pursue medicine. Now that program is changing.
    STAT · 13h ago↗ source
  • Opinion: The U.S. pharmaceutical supply chain problem is not about China
    The national security framing of the discussion around pharmaceutical supply chain vulnerabilities is a distraction, writes Pooja Yerramilli.
← prev
page 2 of 75
next →
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
STAT · 13h ago
↗ source
  • Senate advances MAHA-friendly bill for food warning labels and junk food ad bans
    Unexpected alliances among Republicans and Democrats were on display over a bill meant to rein in ultra-processed foods.
    STAT · 13h ago↗ source
  • STAT+: White House offers its science blueprint: More AI, less life sciences
    The Trump administration released its blueprint for U.S. science, calling for shifting hundreds of billions of research dollars from universities to industry.
    STAT · 13h ago↗ source
  • Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
    Sanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis, admitting that a drug once tipped as a potential blockbuster “would not represent a meaningful improvement” to exis…
    Fierce Biotech · 16h ago↗ source
  • Gene editor Scribe starts second-half IPO spree with $129M listing
    A nine-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna is kicking off a run of biotech IPOs set for this year's second half. Scribe Therapeutics priced its $128.7 million
    Endpoints · 19h ago↗ source
  • Scribe secures $129M in a rare gene editing IPO
    <figure><div><img src="https://imgproxy.divecdn.com/v0D5Ajbuzjf7G4SQRuR5yVFGXoGWXxkevKZwUQRcJjs/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTU2MTc2MTM5LmpwZ…
    BioPharma Dive · 20h ago↗ source
  • Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
    In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.
    Fierce Biotech · 20h ago↗ source
  • FDA panel endorses broader use of certain peptides
    <figure><div><img src="https://imgproxy.divecdn.com/d2JyuXgmLsPVrlZlLVlPLECICsiII5W1r34tQBQf49c/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjI3NzEwNTIwX0w2O…
    BioPharma Dive · 20h ago↗ source
  • STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
    The panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.
    STAT · 1d ago↗ source
  • Updated: FDA adcomm backs popular wellness peptides, despite staff concerns
    An FDA advisory committee voted to recommend expanding access to popular peptides used by health and wellness enthusiasts for repairing muscles, healing injuries, boosting metabolism and reducing i…
    Endpoints · 1d ago↗ source
  • FDA to end pilot aimed at preventing production issues
    The FDA said it will end a pilot that was intended to help drugmakers proactively address production issues. Few companies took advantage of the program during its three-year run. In April 2027,…
    Endpoints · 1d ago↗ source
  • Update: FDA does not freeze CRL trove as ‘radical transparency’ push hits speedbump
    An unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, alleging that the policy “contravenes decades of agency practice.”
    BioSpace · 1d ago↗ source
  • U.S. health officials are investigating a new outbreak of a diarrhea-causing parasite
    Federal health officials are investigating a new outbreak involving the diarrhea-causing parasite cyclospora.
    STAT · 1d ago↗ source
  • Chutes & Ladders—Biogen R&D vet gets in Formation
    AI-focused Formation Bio has found a new chief scientist with extensive experience in biotech, Big Pharma and academia. Michael Ehlers, M.D., Ph.D., is joining the 2025 Fierce 15 honoree as chief s…
    Fierce Biotech · 1d ago↗ source
  • STAT+: European regulators take steps to bolster clinical trial transparency
    The European Medicines Agency is taking what advocacy groups are calling unexpectedly “rapid action” to ensure that clinical trial results are made public as required by law.
    STAT · 1d ago↗ source
  • STAT+: Popular insulin product enters shortage as other pens leave market
    The Lantus Solostar insulin pen isn't in official FDA shortage, but patients are having a tough time finding it.
    STAT · 1d ago↗ source
  • Senate health panel delays vote on CDC nominee
    Too few senators were in attendance to proceed with a vote on the CDC director nominee.
    STAT · 1d ago↗ source
  • Sartorius reduces revenue by €26M to refund Trump tariffs to customers
    Sartorius appears to be the first life science company to detail how tariff refunds are affecting its revenue, following the US Supreme Court decision to block some of President Donald Trump’s levi…
    Endpoints · 1d ago↗ source
  • Lilly, with new data, to seek FDA approval of obesity drug retatrutide
    <figure><div><img src="https://imgproxy.divecdn.com/x5fF_ZCHHBjPFAGFuuKXSVkAgBGYTo2hZBIz9OcQdEo/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDkyNDczMjEzLmpwZ…
    BioPharma Dive · 1d ago↗ source
  • STAT+: What’s in the last-minute flurry of health care bills?
    Congress is scrambling to advance a slew of health care bills before an August recess. Price transparency and prior authorization top the list.
    STAT · 1d ago↗ source
  • FDA panel confronting peptide controversy
    Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
    STAT · 1d ago↗ source
  • Merck CEO cautions Congress on imposing limits on Chinese dealmaking
    Merck CEO Rob Davis said he has warned Congress and the Trump administration that if they cut off or hamper US-China dealmaking, the US could lose its status as the world's biotech leader. China-…
    Endpoints · 1d ago↗ source
  • Scancell plans Neuphoria merger; AstraZeneca wins EU nod for cancer drug
    Scancell to merge into Neuphoria: Scancell plans to take over Neuphoria Therapeutics' Nasdaq listing {$NEUP} and change the ticker to SCLT. The company eyes up to $89 million in equity and ...
    Endpoints · 1d ago↗ source